NOTA Laboratories LLC
NOTA Laboratories is focused on developing innovative nitric oxide (NO) delivery systems and applications to treat and prevent a wide range of life-threatening illnesses and conditions. Their mission is to harness the therapeutic properties of NO as an antimicrobial, antiviral, anti-inflammatory, and anti-thrombotic agent across various medical fields. Founded in 2014, the company has developed proprietary platform technologies, including the NOGEN and LANOR systems, which generate NO on-demand for medical use. They are engaged in multiple applications such as neonatal pulmonary hypertension, open heart surgery, respiratory infections, COPD, and catheter lock solutions, with a focus on safety, efficacy, and cost-effectiveness.
Industries
Nr. of Employees
small (1-50)
Products
Electrochemical on-demand NO generation system for hospital use
A cartridge-based electrochemical system that generates regulated high-concentration nitric oxide for extended clinical applications (e.g., extracorporeal sweep gas), controlled via current/voltage and in-line sensing.
Photochemical UV-LED NO generation system for portable/home use
A compact system using UV/LED illumination of a coated film cassette to photochemically release and modulate nitric oxide; design emphasizes low cost, small size, and battery operation for ambulatory and home settings.
NO-releasing catheter lock and disposable infection-control formats
Local NO-releasing formulations and disposable products designed to prevent microbial growth and clotting in catheter lines and to provide single-use infection-control options (examples include topical sprays, mask sachets, and catheter disposables).
Electrochemical on-demand NO generation system for hospital use
A cartridge-based electrochemical system that generates regulated high-concentration nitric oxide for extended clinical applications (e.g., extracorporeal sweep gas), controlled via current/voltage and in-line sensing.
Photochemical UV-LED NO generation system for portable/home use
A compact system using UV/LED illumination of a coated film cassette to photochemically release and modulate nitric oxide; design emphasizes low cost, small size, and battery operation for ambulatory and home settings.
NO-releasing catheter lock and disposable infection-control formats
Local NO-releasing formulations and disposable products designed to prevent microbial growth and clotting in catheter lines and to provide single-use infection-control options (examples include topical sprays, mask sachets, and catheter disposables).
Services
Collaborative product and engineering development agreements with manufacturing partners to scale device production and integrate with existing medical equipment.
Collaborative preclinical studies using in vitro and in vivo models to assess antimicrobial, antiviral, and respiratory effects of NO-based therapeutics.
Regulatory planning and strategy support drawing on regulatory leadership experience to advance investigational products toward clinical evaluation.
Development of embedded controllers and sensor-driven dosing systems for regulated therapeutic gas delivery, aligned with medical device software standards.
Collaborative product and engineering development agreements with manufacturing partners to scale device production and integrate with existing medical equipment.
Collaborative preclinical studies using in vitro and in vivo models to assess antimicrobial, antiviral, and respiratory effects of NO-based therapeutics.
Regulatory planning and strategy support drawing on regulatory leadership experience to advance investigational products toward clinical evaluation.
Development of embedded controllers and sensor-driven dosing systems for regulated therapeutic gas delivery, aligned with medical device software standards.
Expertise Areas
- Nitric oxide delivery systems development
- Medical device design and engineering
- Preclinical infectious disease and respiratory models
- Respiratory and cardiovascular therapeutic applications
Key Technologies
- Electrochemical nitric oxide generation
- Photochemical UV-LED nitric oxide generation from donor films
- NO‑releasing polymers and chemistries
- Sensor-integrated dosing control systems
News & Updates
In October 2022, NOTA Laboratories announced the completion of its second round of financing led by Pegasus Tech Ventures, a global venture capital firm. This capital will support the development of nitric oxide therapies. The company has two patented platform technologies, NOGEN and LANOR, which generate NO on-demand and are suitable for hospital, clinic, and in-home use.
In September 2022, NOTA Laboratories signed a joint development agreement with NGK Sparkplugs of Japan. NGK owns CAIRE Inc., a major oxygen concentrator supplier. The collaboration aims to develop NO delivery solutions for respiratory and other medical applications, leveraging NOTA's proprietary NO generation technologies.
In October 2022, NOTA Laboratories announced the completion of its second round of financing led by Pegasus Tech Ventures, a global venture capital firm. This capital will support the development of nitric oxide therapies. The company has two patented platform technologies, NOGEN and LANOR, which generate NO on-demand and are suitable for hospital, clinic, and in-home use.
In September 2022, NOTA Laboratories signed a joint development agreement with NGK Sparkplugs of Japan. NGK owns CAIRE Inc., a major oxygen concentrator supplier. The collaboration aims to develop NO delivery solutions for respiratory and other medical applications, leveraging NOTA's proprietary NO generation technologies.